The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
The FKBP51 Glucocorticoid Receptor Co-Chaperone: Regulation, Function, and Implications in Health and Disease
Open accessAbstract
Among the chaperones and co-chaperones regulating the glucocorticoid receptor (GR), FK506 binding protein (FKBP) 51 is the most intensely investigated across different disciplines. This review provides an update on the role of the different co-chaperones of Hsp70 and Hsp90 in the regulation of GR function. The development leading to the focus on FKBP51 is outlined. Further, a survey of the vast literature on the mechanism and function of FKBP51 is provided. This includes its structure and biochemical function, its regulation on different levels—transcription, post-transcription, and post-translation—and its function in signaling pathways. The evidence portraying FKBP51 as a scaffolding protein organizing protein complexes rather than a chaperone contributing to the folding of individual proteins is collated. Finally, FKBP51’s involvement in physiology and disease is outlined, and the promising efforts in developing drugs targeting FKBP51 are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 9×
“The original discovery of FK506 binding protein (FKBP) 51 was described more than 25 years ago alongside the analysis of steroid receptor complex components [1].”
BackgroundInfluentialAKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Schopf, F. H., Biebl, M. M., & Buchner, J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.20 · Cited by 1,540
Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions
Klengel, T., Mehta, D., Anacker, C., Rex-Haffner, M., Pruessner, J. C., Pariante, C. M., Pace, T. W. W., Mercer, K. B., Mayberg, H. S., Bradley, B., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3275 · Cited by 1,447
Self-citationStructure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Binder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977
Self-citationQuantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition
Taipale, M., Krykbaeva, I., Koeva, M., Kayatekin, C., Westover, K. D., Karras, G. I., & Lindquist, S. (2012) · Cell · doi:10.1016/j.cell.2012.06.047 · Cited by 879
Zhao, R., Davey, M., Hsu, Y.-C., Kaplanek, P., Tong, A., Parsons, A. B., Krogan, N., Cagney, G., Mai, D., Greenblatt, J., et al. (2005) · Cell · doi:10.1016/j.cell.2004.12.024 · Cited by 819
Reduced levels of hsp90 compromise steroid receptor action in vivo
Picard, D., Khursheed, B., Garabedian, M. J., Fortin, M. G., Lindquist, S., & Yamamoto, K. R. (1990) · Nature · doi:10.1038/348166a0 · Cited by 787 · cited 1×
“The first confirmed chaperone found associated with SRs was heat shock protein (Hsp) 90 [4,23,24].”
BackgroundThe neurobiology of depression: An integrated view
Dean, J., & Keshavan, M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.025 · Cited by 765
FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt
Pei, H., Li, L., Fridley, B. L., Jenkins, G. D., Kalari, K. R., Lingle, W., Petersen, G., Lou, Z., & Wang, L. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.016 · Cited by 709
Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M., & Kudo, I. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003504200 · Cited by 708
Overview of nomenclature of nuclear receptors
Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.2 · Cited by 688 · cited 1×
“NRs are grouped into seven subfamilies, NR0-6, based on their homology [18].”
BackgroundWochnik, G. M., Rüegg, J., Abel, G. A., Schmidt, U., Holsboer, F., & Rein, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m407498200 · Cited by 638
Self-citationGlucocorticoid receptor control of transcription: precision and plasticity via allostery
Weikum, E. R., Knuesel, M. T., Ortlund, E. A., & Yamamoto, K. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.152 · Cited by 533
The glucocorticoid responses are shaped by molecular chaperones
Grad, I., & Picard, D. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.018 · Cited by 423
Disassembly of Transcriptional Regulatory Complexes by Molecular Chaperones
Freeman, B. C., & Yamamoto, K. R. (2002) · Science · doi:10.1126/science.1073051 · Cited by 400
Kirschke, E., Goswami, D., Southworth, D., Griffin, P. R., & Agard, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.04.038 · Cited by 399
Freeman, B. C., Toft, D. O., & Morimoto, R. I. (1996) · Science · doi:10.1126/science.274.5293.1718 · Cited by 370
The Hsp90‐binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo
Riggs, D. L., Roberts, P. J., Chirillo, S. C., Cheung‐Flynn, J., Prapapanich, V., Ratajczak, T., Gaber, R., Picard, D., & Smith, D. F. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg108 · Cited by 353 · cited 4×
“The FK1 domain is the primary determi ant for the divergent actions of FKBP51 and FKBP52 on GR [7,9].”
BackgroundInfluentialRole of hsp90 and the hsp90-binding immunophilins in signalling protein movement
Pratt, W. B., Galigniana, M. D., Harrell, J. M., & DeFranco, D. B. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.02.004 · Cited by 285 · cited 3×
“Briefly, an important group of Hsp90 cofactors competes for access to Hsp90 and the associated hetero-complexes by binding to the N-terminal EEVD-motif of Hsp90 through their tetratricopeptide repeat (TPR) motif domain [5,71,89].”
BackgroundLekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284
Lee, R. S., Tamashiro, K. L. K., Yang, X., Purcell, R. H., Harvey, A., Willour, V. L., Huo, Y., Rongione, M., Wand, G. S., & Potash, J. B. (2010) · Endocrinology · doi:10.1210/en.2010-0225 · Cited by 275
FKBP51 and FKBP52 in signaling and disease
Storer, C. L., Dickey, C. A., Galigniana, M. D., Rein, T., & Cox, M. B. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.08.001 · Cited by 266 · cited 5×
“The structures of the FK1s of the two immunophilins differ around the PPIase pocket by several residues of a proline-rich region [74,98,102], which likely causes differential protein interaction and the differential effects on GR activity [74,96].”
BackgroundInfluentialSelf-citationZimmermann, P., Brückl, T., Nocon, A., Pfister, H., Binder, E. B., Uhr, M., Lieb, R., Moffitt, T. E., Caspi, A., Holsboer, F., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111577 · Cited by 262
Sinars, C. R., Cheung-Flynn, J., Rimerman, R. A., Scammell, J. G., Smith, D. F., & Clardy, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0231020100 · Cited by 254
Selective inhibitors of the FK506-binding protein 51 by induced fit
Gaali, S., Kirschner, A., Cuboni, S., Hartmann, J., Kozany, C., Balsevich, G., Namendorf, C., Fernandez-Vizarra, P., Sippel, C., Zannas, A. S., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1699 · Cited by 245 · cited 3×
“In recent years, ligands for FKBP51 have been synthesized that are selective in the sense that they do not bind to FKBP52 [241,242].”
BackgroundGaligniana, M. D., Radanyi, C., Renoir, J.-M., Housley, P. R., & Pratt, W. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010809200 · Cited by 236 · cited 1×
“The PPIase domain, however, likely plays a crucial role in regulating GR, with effects on hormone binding affinity and nuclear translocation [7,9,74,75].”
BackgroundAppel, K., Schwahn, C., Mahler, J., Schulz, A., Spitzer, C., Fenske, K., Stender, J., Barnow, S., John, U., Teumer, A., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.81 · Cited by 234
Smith, D. F., Faber, L. E., & Toft, D. O. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39693-0 · Cited by 221 · cited 1×
“The original discovery of FK506 binding protein (FKBP) 51 was described more than 25 years ago alongside the analysis of steroid receptor complex components [1].”
BackgroundIntronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids
Hubler, T. R., & Scammell, J. G. (2004) · Cell Stress & Chaperones · doi:10.1379/csc-32r.1 · Cited by 201
Barent, R. L., Nair, S. C., Carr, D. C., Ruan, Y., Rimerman, R. A., Fulton, J., Zhang, Y., & Smith, D. F. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.3.0075 · Cited by 190 · cited 2×
“Amino acids downstream of the TPR domain at the very C-terminal end of FKBP51 have also been reported to contribute to Hsp90 binding [101].”
BackgroundPirkl, F., & Buchner, J. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4595 · Cited by 179 · cited 10×
“Altogether, this multitude of regulatory mechanisms allows for a complex modulation of the FKBP51-GR system in The FK1 domain is the primary determi ant for the divergent actions of FKBP51 and FKBP52 on GR [7,9].”
BackgroundInfluentialMenke, A., Arloth, J., Pütz, B., Weber, P., Klengel, T., Mehta, D., Gonik, M., Rex-Haffner, M., Rubel, J., Uhr, M., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.331 · Cited by 177
Direct, Androgen Receptor-Mediated Regulation of the FKBP5 Gene via a Distal Enhancer Element
Magee, J. A., Chang, L.-W., Stormo, G. D., & Milbrandt, J. (2006) · Endocrinology · doi:10.1210/en.2005-1001 · Cited by 174
Freeman, B. C., Felts, S. J., Toft, D. O., & Yamamoto, K. R. (2000) · Genes & Development · doi:10.1101/gad.14.4.422 · Cited by 168
Ni, L., Yang, C.-S., Gioeli, D., Frierson, H., Toft, D. O., & Paschal, B. M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01891-08 · Cited by 155 · cited 2×
“It should be mentioned, though, that some of the effects of FK506 have been ascribed specifically to the inhibition of FKBP51, in particular by blocking the AR and thereby inhibiting prostate cancer cell growth [229,230].”
BackgroundMenke, A., Klengel, T., Rubel, J., Brückl, T., Pfister, H., Lucae, S., Uhr, M., Holsboer, F., & Binder, E. B. (2013) · Genes, Brain and Behavior · doi:10.1111/gbb.12026 · Cited by 151 · cited 2×
“[187] Genotype (rs1360780) Inpatients in a depressive episode (n = 68) and healthy controls (n = 87) Significant interaction between MDD and T allele on GR-stimulated FKBP5 mRNA expression (reduced induction of FKBP5 mRNA in T carriers).”
BackgroundRiggs, D. L., Cox, M. B., Tardif, H. L., Hessling, M., Buchner, J., & Smith, D. F. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00985-07 · Cited by 150 · cited 7×
“For example, while FKBP52 potentiates GR function in the yeast model [9,74], its overexpression in mammalian cells produces very little, if any, effect on GR, likely due to the presence of numerous other TPR cofactors that already promote GR function [7,71].”
BackgroundInfluentialConformational Switching of the Molecular Chaperone Hsp90 via Regulated Phosphorylation
Soroka, J., Wandinger, S. K., Mäusbacher, N., Schreiber, T., Richter, K., Daub, H., & Buchner, J. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.12.031 · Cited by 139 · cited 1×
“While clear evidence has been provided for the involvement of PP5’s phosphatase activity in GR function through changing both Hsp90 and GR phosphorylation [79,80,90], the role, if any, of the PPIase activity of GR-regulating immunophilins such as FKBP51 and FKBP52 remains unknown [6,74].”
BackgroundThe Plasticity of the Hsp90 Co-chaperone System
Sahasrabudhe, P., Rohrberg, J., Biebl, M. M., Rutz, D. A., & Buchner, J. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.08.004 · Cited by 136 · cited 1×
“Both inhibitory and stimulatory effects on GR function have been described for these proteins, depending on their abundance as well as the cellular context [27,39,68,69,76,83,87].”
BackgroundGlucocorticoid receptor activates poised FKBP51 locus through long-distance interactions
Paakinaho, V., Makkonen, H., Jääskeläinen, T., & Palvimo, J. J. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0443 · Cited by 122
Pharmacological Inhibition of the Psychiatric Risk Factor FKBP51 Has Anxiolytic Properties
Hartmann, J., Wagner, K. V., Gaali, S., Kirschner, A., Kozany, C., Ruhter, G., Dedic, N., Hausl, A. S., Hoeijmakers, L., Westerholz, S., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4024-14.2015 · Cited by 109 · cited 1×
“Nevertheless, these compounds are very promising as they show antidepressant-like, anxiolytic and pain-relieving effects in mouse models [241,243,244].”
BackgroundPeriyasamy, S., Hinds, T., Shemshedini, L., Shou, W., & Sanchez, E. R. (2010) · Oncogene · doi:10.1038/onc.2009.458 · Cited by 108 · cited 2×
“It should be mentioned, though, that some of the effects of FK506 have been ascribed specifically to the inhibition of FKBP51, in particular by blocking the AR and thereby inhibiting prostate cancer cell growth [229,230].”
BackgroundVelders, F. P., Kuningas, M., Kumari, M., Dekker, M. J., Uitterlinden, A. G., Kirschbaum, C., Hek, K., Hofman, A., Verhulst, F. C., Kivimaki, M., et al. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.01.003 · Cited by 106
Genetic Variants in FKBP5 Affecting Response to Antidepressant Drug Treatment
Kirchheiner, J., Lorch, R., Lebedeva, E., Seeringer, A., Roots, I., Sasse, J., & Brockmöller, J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.7.841 · Cited by 104 · cited 1×
“[197] Genoytpe (rs3800373, rs1360780) N = 304 depressive inpatients with unipolar or bipolar depression Carriers of the FKBP5 variants had a trend toward a higher chance to response (mainly in those treated with antidepressant drug combinations or with venlafaxine)”
BackgroundFKBP5 polymorphism is associated with major depression but not with bipolar disorder
Szczepankiewicz, A., Leszczyńska-Rodziewicz, A., Pawlak, J., Narozna, B., Rajewska-Rager, A., Wilkosc, M., Zaremba, D., Maciukiewicz, M., & Twarowska-Hauser, J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.04.002 · Cited by 100
Newton, R., Shah, S., Altonsy, M. O., & Gerber, A. N. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.777318 · Cited by 91 · cited 1×
“Given the known function of glucocorticoids and GR on inflammation [128,129], it is not surprising that FKBP51 has been shown to present direct and indirect effects on immune and inflammatory pathways as well.”
BackgroundRole of FKBP5 in emotion processing: results on amygdala activity, connectivity and volume
Holz, N. E., Buchmann, A. F., Boecker, R., Blomeyer, D., Baumeister, S., Wolf, I., Rietschel, M., Witt, S. H., Plichta, M. M., Meyer-Lindenberg, A., et al. (2015) · Brain Structure and Function · doi:10.1007/s00429-014-0729-5 · Cited by 82 · cited 1×
“the rs1360780 have been associated with altered volumes of the dorsal anterior and posterior cingulate cortexes [249], right amygdala [250], left amygdala [251], and the right middle and inferior orbitofrontal regions [250].”
BackgroundFani, N., King, T. Z., Shin, J., Srivastava, A., Brewster, R. C., Jovanovic, T., Bradley, B., & Ressler, K. J. (2016) · Depression and Anxiety · doi:10.1002/da.22483 · Cited by 80 · cited 3×
“(PTSD) [172,173], suicide [174], attention-deficit/hyperactivity disorder [175], anxiety [176], and the effects of early trauma and stress in general [177–179].”
BackgroundHNRC, Tatro, E. T., Everall, I. P., Masliah, E., Hult, B. J., Lucero, G., Chana, G., Soontornniyomkij, V., & Achim, C. L. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9146-6 · Cited by 75
Hohne, N., Poidinger, M., Merz, F., Pfister, H., Bruckl, T., Zimmermann, P., Uhr, M., Holsboer, F., & Ising, M. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu087 · Cited by 74
Dackis, M. N., Rogosch, F. A., Oshri, A., & Cicchetti, D. (2012) · Development and Psychopathology · doi:10.1017/s0954579412000673 · Cited by 71
Hsp110 Chaperones Control Client Fate Determination in the Hsp70–Hsp90 Chaperone System
Mandal, A. K., Gibney, P. A., Nillegoda, N. B., Theodoraki, M. A., Caplan, A. J., & Morano, K. A. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-09-0779 · Cited by 66 · cited 1×
“[63,64] HSPBP1 (Hsp70 binding protein 1) Nucleotide exchange factor of Hsp70.”
BackgroundStructural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90
Bracher, A., Kozany, C., Thost, A.-K., & Hausch, F. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911013862 · Cited by 62 · cited 1×
“The development of these FKBP51 ligands has greatly benefitted from high resolution crystal structure analyses [245,246].”
BackgroundLevran, O., Randesi, M., Li, Y., Rotrosen, J., Ott, J., Adelson, M., & Jeanne Kreek, M. (2014) · Annals of Human Genetics · doi:10.1111/ahg.12064 · Cited by 62 · cited 1×
“With different degrees of involvement, FKBP51 has been previously associated with substance abuse [166,167], autism [168], bipolar disorder [169,170], depression [12,116], schizophrenia [171], post-traumatic stress disorder”
BackgroundFKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications
Gassen, N. C., Hartmann, J., Zannas, A. S., Kretzschmar, A., Zschocke, J., Maccarrone, G., Hafner, K., Zellner, A., Kollmannsberger, L. K., Wagner, K. V., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.38 · Cited by 62 · cited 2×
“The dependency of antidepressant drug treatment on the FKBP51 levels has been shown in several studies employing human cell lines, mouse models, and peripheral blood cells from depressed patients and healthy controls [12,141,147,151,205].”
BackgroundSelf-citationCox, M. B., Riggs, D. L., Hessling, M., Schumacher, F., Buchner, J., & Smith, D. F. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0547 · Cited by 60 · cited 1×
“As opposed to FKBP52, FKBP51’s sequence lacks a phosphorylation site on its FK linker region (a seven- to nine-amino-acid loop that connects the FK1 and FK2 domains) [123].”
BackgroundKumar, R., Moche, M., Winblad, B., & Pavlov, P. F. (2017) · Scientific Reports · doi:10.1038/s41598-017-14731-z · Cited by 40
Lahti, J., Ala-Mikkula, H., Kajantie, E., Haljas, K., Eriksson, J. G., & Räikkönen, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.022 · Cited by 37 · cited 1×
“[191] Genotype (rs1360780, rs9470080, rs9394309) N = 1431 participants with available data on early life stress and depressive symptoms at midlife FKBP5 SNPs interacted with early life stress exposure, but not with recent stressful life events, in predicting self-reported depressive symptoms in midlife.”
BackgroundRecent Progress in FKBP Ligand Development
Feng, X., Pomplun, S., & Hausch, F. (2015) · Current Molecular Pharmacology · doi:10.2174/1874467208666150519113313 · Cited by 22 · cited 1×
“In recent years, ligands for FKBP51 have been synthesized that are selective in the sense that they do not bind to FKBP52 [241,242].”
BackgroundFrodl, T., Carballedo, A., Frey, E.-M., O'Keane, V., Skokauskas, N., Morris, D., Gill, M., Hughes, M. M., Harkin, A., & Connor, T. (2014) · Development and Psychopathology · doi:10.1017/s0954579414000972 · Cited by 20
Cited by
Molecular pathways of major depressive disorder converge on the synapse
Fries, G. R., Saldana, V. A., Finnstein, J., & Rein, T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01806-1 · Cited by 504
Self-citationUnderstanding the Complex of Suicide in Depression: from Research to Clinics
Orsolini, L., Latini, R., Pompili, M., Serafini, G., Volpe, U., Vellante, F., Fornaro, M., Valchera, A., Tomasetti, C., Fraticelli, S., et al. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0171 · Cited by 406
Substance P and pain chronicity
Zieglgänsberger, W. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-2922-y · Cited by 276
Lee, E.-H., Park, J.-Y., Kwon, H.-J., & Han, P.-L. (2021) · Nature Communications · doi:10.1038/s41467-021-26968-4 · Cited by 82
van Doeselaar, L., Stark, T., Mitra, S., Yang, H., Bordes, J., Stolwijk, L., Engelhardt, C., Kovarova, V., Narayan, S., Brix, L. M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300722120 · Cited by 30
Metadata
- Authors
- Fries, G., Gassen, N., & Rein, T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-12-05
- Volume
- 18
- Issue
- 12
- Pages
- 2614
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2774953348
- Cited by
- 166
- References
- 64
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.